Table 2.

Distribution of moderate-efficacy DMTs before the escalation and of high-efficacy DMTs after escalation in the ESC group after PS matching.

First DMT (before the escalation)	Pts, n (%)
Interferon beta 1a i.m.	72 (19.56)
Interferon beta 1a s.c.	162 (44.63)
Interferon beta 1b s.c.	71 (19.56)
Glatiramer acetate	33 (9.09)
Azathioprine	25 (6.89)
High-efficacy DMTs at the escalation
Alemtuzumab	6 (1.65)
Fingolimod	141 (38.84)
Natalizumab	156 (42.98)
Mitoxantrone	51 (14.05)
Ocrelizumab	8 (2.20)
Cladribine	1 (0.28)

DMT, disease-modifying therapy; ESC, escalation approach; i.m., intramuscular; n, number; PS, propensity score; Pts, patients; s.c., subcutaneous.